TPOXX (tecovirimat) IV

About SIGA Technologies

SIGA Technologies' mission is to protect humanity against severe infectious diseases by developing and commercializing critical medical countermeasures. Its core achievement is the successful development and regulatory approval of TPOXX® (tecovirimat), the first oral antiviral for smallpox, which forms the cornerstone of a durable, government-focused revenue stream. The company's strategy is to deepen its role as an essential biodefense partner to the U.S. and allied governments while expanding TPOXX's label into new indications like post-exposure prophylaxis and pediatric use, thereby solidifying its market leadership in the orthopoxvirus space.

Therapeutic Areas

Other Treatment of Smallpox Drugs